文献速递药物不良反应与药物警戒

阿伐替尼上市后药物警戒研究:基于FAERS数据库的不良事件数据挖掘与分析

A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
PubMed 文献 · Br J Clin Pharmacol · 2023-02-06

本研究基于FAERS数据库截至2022年6月的3120例阿伐替尼相关报告,采用不成比例分析和贝叶斯分析检测到331个不良事件信号,发现皮肤纹理异常和执行功能障碍信号强度高,老年男性患者更易发生严重不良事件,性别、年龄和发病时间均与死亡显著相关。

要点

  • 共纳入3120例阿伐替尼相关报告,44%发生在用药后30天内。
  • 检测到331个不良事件信号,皮肤纹理异常和执行功能障碍信号强度高。

核心结论

  • 阿伐替尼相关不良事件谱广泛,皮肤纹理异常和执行功能障碍信号强度高。
  • 老年男性患者严重不良事件风险更高,尤其用药后30天内需警惕。

研究设计与样本

  • 基于美国FDA不良事件报告系统(FAERS)的上市后药物警戒研究。
  • 提取截至2022年6月所有阿伐替尼相关报告,共3120例。
  • 采用不成比例分析和贝叶斯分析计算ROR、PRR、IC和EBGM评估信号。

主要发现

  • 3120例报告中44%在开始阿伐替尼后30天内报告。
  • 共检测到331个不同的不良事件信号。
  • 皮肤纹理异常和执行功能障碍报告数少但信号强度高,提示强相关。
  • 出血组与非出血组之间无显著差异。

关键数值与推荐

  • 采用ROR、PRR、IC和EBGM四种方法进行信号检测。
  • 性别、年龄和发病时间在出血/非出血、严重/非严重、死亡/非死亡不良事件间具有可比性。

临床怎么用

  • 临床处方阿伐替尼时应特别关注老年男性患者,尤其用药后30天内。
  • 对皮肤纹理异常和执行功能障碍保持警惕,即使报告数少也可能信号强。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Avapritinib was first approved by the FDA in January 2020 and represents the first precision-targeted drug for gastrointestinal stromal tumours. However, there is a lack of large-scale data relating to adverse events (AEs) related to its use. We aimed to explore the avapritinib-related AEs in real-world practice based on the post-marketing data. METHODS: We extracted all avapritinib-related reports submitted to the FDA Adverse Event Reporting System (FAERS) by June 2022. Based on disproportionality analysis and Bayesian analysis, we then calculated the reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC) and empirical Bayes geometric mean (EBGM) to evaluate whether there is a significant association between avapritinib and AEs. Gender, age and time to onset were comparable between haemorrhage/non-haemorrhage, serious/non-serious, death/non-death AEs, respectively. RESULTS: In total, 3120 cases related to avapritinib were documented in the FAERS database, and 44% were reported within 30 days of commencing avapritinib. A total of 331 different AE signals were detected, and no significant differences between males and females was identified. Although the number of AEs associated with an abnormal skin texture and executive dysfunction was small, the signal intensity is high, suggesting that these events are strongly correlated with avapritinib. Subgroup analysis showed that elderly male patients were more likely to suffer from serious AEs compared to females (P < .01), but there was no significant difference between the haemorrhage group and the non-haemorrhage group. Analysis of fatalities due to avapritinib-related AEs indicated that sex, age and time-to-onset were all significantly related to death (P < .05). CONCLUSION: Our study provides a more precise description of the incidence and characteristics of AEs after using avapritinib, clinicians should be particularly careful when prescribing avapritinib to elderly male patients, especially within the 30 days.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Rong L, Xie M, Jiang M, et al. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol. 2023. PMID: 36702463. doi:10.1111/bcp.15673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。